Quantcast

Latest Ribbon symbolism Stories

2014-05-09 23:05:43

Part 2 in this Genomic Series will help cancer researchers better understand how genomic data can be used to gain insights into drug resistance, and will focus specifically on resistance and response in a specific subtype of breast cancer. The live broadcast takes place on Wednesday, May 28, 2014 at 1 p.m. EDT. Toronto, Canada (PRWEB) May 09, 2014 Next generation sequencing (NGS) has posed new challenges and opportunities in cancer treatment and drug development. NGS has allowed...

2014-05-09 19:06:35

Massachusetts Institute of Technology Nanoparticles that stagger delivery of 2 drugs knock out aggressive tumors in mice MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast...

2014-05-09 13:00:57

Virginia Commonwealth University Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers at Virginia Commonwealth University Massey Cancer Center suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast...

2014-05-08 23:12:02

ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020" to its huge collection of research reports. Get full report with TOC at http://www.researchmoz.us/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-report.html. Albany,New York (PRWEB) May 08, 2014 Researchmoz presents this most up-to-date research on "Breast Cancer Therapeutics in...

2014-05-08 09:30:29

AURORA, the first international molecular screening program for metastatic breast cancer, presented at IMPAKT Breast Cancer Conference While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant...

2014-05-07 04:22:16

OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that it has obtained the exclusive global rights to certain Xenomouse(R) antibodies generated by Amgen and to ImmunoGen's maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic...

2014-05-06 16:32:54

13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014. Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO Product revenue was $67.0 million in the first quarter of 2014, compared with $62.7 million for the first quarter of 2013, an increase of 7 percent. Total revenue for...

2014-05-05 20:23:45

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/treatments/hormone_sensitive_breast_cancer_global_clinical_trials_review_h1_2014.htmlHormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2014" provides...

2014-05-05 12:29:18

SCHAUMBURG, Ill., May 5, 2014 /PRNewswire-USNewswire/ -- Edgar Staren, MD, Ph.D., MBA, President and CEO of Cancer Treatment Centers of America® (CTCA) Medicine and Science has been selected to present new research on approaches to the treatment of primary and recurrent breast cancer at the American Society of Breast Surgeons 15(th) Annual Meeting in Las Vegas, NV on Friday, May, 2, 2014. Dr. Staren presented his abstract titled "Initial Experience with Genomic Profiling of...

2014-05-05 10:25:43

A new study reports that sleep efficiency, a ratio of time asleep to time spent in bed, is predictive of survival time for women with advanced breast cancer. Results show that higher sleep efficiency was significantly associated with lower mortality over the ensuing six years, an effect that remained after adjusting for baseline prognostic factors such as age, estrogen receptor status and treatments received. Mean survival was 68.9 months for efficient sleepers compared with 33.2 months...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related